Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Differentiation of Common Myeloid Progenitor Cells01:15

Differentiation of Common Myeloid Progenitor Cells

Common myeloid progenitors (CMPs) are oligopotent cells that can differentiate into granulocytes and macrophages. Granulocytes and macrophages are essential for protecting the body against bacterial, viral, or fungal infections. They migrate from the bone marrow into the circulating blood to reach specific tissue sites where they differentiate and help in immune surveillance. However, they survive only for a few days and must be continuously made available to the organism to maintain a robust...
Regulation of Hematopoietic Stem Cells01:01

Regulation of Hematopoietic Stem Cells

All blood and immune cells are produced from the multipotent hematopoietic stem cells (HSCs) by the process of hematopoiesis. However, they all have a limited life span. In addition, many are depleted in immune surveillance or combatting an injury or infection. This makes blood one of the most regenerative tissues. Hematopoiesis helps replenish these blood and immune cells, restoring the body's normal functioning. However, overproduction of blood and immune cells can make them cancerous or...
Mesenchymal Stem Cells01:19

Mesenchymal Stem Cells

Mesenchymal stem cells (MSCs) are adult stem cells that can differentiate into most connective tissue cell types, except for hematopoietic cells, depending upon the source of MSCs. For example, bone-marrow-derived MSCs (BM-MSCs) can differentiate into osteocytes, hepatocytes, and pancreatic and neuronal cells. MSCs can be isolated from various sources such as bone marrow, placenta, adipose tissue, teeth, and Wharton’s jelly, a gelatinous substance in the umbilical cord. The ease of their access...
Cytotoxic T Cells-mediated Immune Response01:27

Cytotoxic T Cells-mediated Immune Response

Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
Stem Cell Therapy for Tissue Regeneration01:21

Stem Cell Therapy for Tissue Regeneration

Stem cell therapy is a method used in regenerative medicine to repair and restore function to damaged tissues and organs. Stem cells have the potential to proliferate and differentiate into various tissue types, making them ideal candidates for tissue regeneration. For example, hematopoietic stem cell transplants are commonly used in blood cancer treatment to replenish damaged bone marrow and restore healthy blood cells.
Types of Stem Cells used in Stem Cell Therapy
The two main cell types that...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Early Peak Systolic Velocity and Trend Variation Predict Stent Patency in Chronic Mesenteric Ischemia and Propose a Post-Intervention Surveillance Algorithm.

Annals of vascular surgery·2026
Same author

High-throughput screening identifies NT-1 that synergizes with MRTX1133 against acquired resistant KRAS<sup>G12D</sup> colorectal cancer.

NPJ precision oncology·2026
Same author

Editor's Note: Cell Cycle-Dependent and Schedule-Dependent Antitumor Effects of Sorafenib Combined with Radiation.

Cancer research·2026
Same author

Editor's Note: Tumorigenic Conversion of Primary Human Esophageal Epithelial Cells Using Oncogene Combinations in the Absence of Exogenous Ras.

Cancer research·2026
Same author

A generalizable cross-continent prediction of esophageal squamous cell carcinoma using the oral microbiome.

Communications medicine·2026
Same author

True hepatic artery aneurysm repair: anatomical complexity and operative adaptability comparing open versus endovascular approach.

HPB : the official journal of the International Hepato Pancreato Biliary Association·2026

Related Experiment Video

Updated: May 10, 2026

Preparation of Myeloid Derived Suppressor Cells (MDSC) from Naive and Pancreatic Tumor-bearing Mice using Flow Cytometry and Automated Magnetic Activated Cell Sorting (AutoMACS)
14:15

Preparation of Myeloid Derived Suppressor Cells (MDSC) from Naive and Pancreatic Tumor-bearing Mice using Flow Cytometry and Automated Magnetic Activated Cell Sorting (AutoMACS)

Published on: June 18, 2012

Myeloid derived suppressor cells: Targets for therapy.

Todd J Waldron1, Jon G Quatromoni, Tatiana A Karakasheva

  • 1Gastroenterology Division; Department of Medicine; University of Pennsylvania; Philadelphia, PA USA ; Abramson Cancer Center; University of Pennsylvania; Philadelphia, PA USA;

Oncoimmunology
|June 5, 2013
PubMed
Summary

Cancer immunotherapy requires overcoming tumor immunosuppression. Myeloid-derived suppressor cells (MDSCs) hinder anti-tumor immunity, but new agents targeting MDSCs show promise for improving treatment efficacy.

Keywords:
CpG oligodeoxynucleotides (ODN)Myeloid derived suppressor cellsRNA aptamercurcumincyclophosphamidedocetaxolgemcitabine

More Related Videos

Isolation and Characterization of Neutrophils with Anti-Tumor Properties
10:15

Isolation and Characterization of Neutrophils with Anti-Tumor Properties

Published on: June 19, 2015

Functional Characterization of Regulatory Macrophages That Inhibit Graft-reactive Immunity
08:41

Functional Characterization of Regulatory Macrophages That Inhibit Graft-reactive Immunity

Published on: June 7, 2017

Related Experiment Videos

Last Updated: May 10, 2026

Preparation of Myeloid Derived Suppressor Cells (MDSC) from Naive and Pancreatic Tumor-bearing Mice using Flow Cytometry and Automated Magnetic Activated Cell Sorting (AutoMACS)
14:15

Preparation of Myeloid Derived Suppressor Cells (MDSC) from Naive and Pancreatic Tumor-bearing Mice using Flow Cytometry and Automated Magnetic Activated Cell Sorting (AutoMACS)

Published on: June 18, 2012

Isolation and Characterization of Neutrophils with Anti-Tumor Properties
10:15

Isolation and Characterization of Neutrophils with Anti-Tumor Properties

Published on: June 19, 2015

Functional Characterization of Regulatory Macrophages That Inhibit Graft-reactive Immunity
08:41

Functional Characterization of Regulatory Macrophages That Inhibit Graft-reactive Immunity

Published on: June 7, 2017

Area of Science:

  • Immunology
  • Oncology
  • Cancer Research

Background:

  • Tumors evade immune detection through immunosuppressive mechanisms.
  • Myeloid-derived suppressor cells (MDSCs) are key mediators of tumor-induced immunosuppression.
  • MDSCs inhibit both innate and adaptive immune responses against cancer.

Purpose of the Study:

  • To investigate the role of MDSCs in tumor immune evasion.
  • To explore strategies for counteracting MDSC-mediated immunosuppression.
  • To identify potential therapeutic targets for enhancing cancer immunotherapy.

Main Methods:

  • Analysis of tumor-derived signals activating MDSCs.
  • Assessment of MDSC suppressive functions on immune cells.
  • Evaluation of novel anti-MDSC agents in preclinical models.

Main Results:

  • Tumor signals activate MDSCs, leading to immune suppression.
  • MDSCs effectively inhibit anti-tumor immune responses.
  • Identified anti-MDSC agents demonstrate potential to restore immune function.

Conclusions:

  • Targeting MDSCs is a viable strategy to enhance cancer immunotherapy.
  • Counteracting MDSC-mediated immunosuppression can improve treatment outcomes.
  • Further development of anti-MDSC therapies is warranted.